Compare FTHM & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | HBIO |
|---|---|---|
| Founded | 2010 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 26.5M |
| IPO Year | 2020 | 2000 |
| Metric | FTHM | HBIO |
|---|---|---|
| Price | $0.72 | $7.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 134.4K | 18.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | $116,176,000.00 |
| Revenue This Year | $11.67 | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $0.38 |
| 52 Week High | $3.37 | $7.63 |
| Indicator | FTHM | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 70.10 |
| Support Level | $0.70 | $5.91 |
| Resistance Level | $0.92 | $7.50 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 10.67 | 86.73 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.